Maximus, Inc.
Maximus, Inc. (MMS) has a dated report snapshot, but its current priced-in claim is temporarily suppressed because the live engine record is unavailable or has changed.
• Maximus runs health and human-services programs for governments, from Medicaid and Medicare enrollment to clinical assessments, delivered through ⟦"digitally enabled contact centers, mail-room operations, and mobile or web-based platforms,"⟧ a recurring-contract business that earns a 22% return on equity. • The stock is unusually cheap on every lens: at about seven times operating income the price sits below what even a steady decline in operating profit would warrant, while the company earns
Is MMS overvalued? See what's priced in →
356 institutional managers reported holding MMS in 13F filings for the quarter ended 2026-03-31. 50 opened new positions that quarter. Held by FMR (Fidelity), BlackRock, Vanguard Group, among others. On the short side, 3.6M shares were sold short as of the 2026-06-15 count, about 7% of shares outstanding (6.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
MMS has cut its share count 12.6% over the past five years, spending $771.67M on repurchases. It pays a dividend, and has paid one every year in our records (17 and counting); the current rate is $1.20 a share annually. Cash returned over the past three years: $192.79M in dividends and $675.55M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at MMS over the trailing three years: 2023: 3 buys totaling $257k; 2024: 11 buys totaling $772k; 2025: 9 buys totaling $124k; 2026: 4 buys totaling $325k. 13 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
MMS's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | -4.1% | -5.8% |
| 2023-11-17 | +4.4% | -0.8% |
| 2024-02-09 | +0.5% | -3.1% |
| 2024-05-10 | -0.7% | +3.5% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
MMS's latest 8-K filings: 2026-05-28 (items 1.01, 2.03, 9.01); 2026-05-07 (items 2.02, 9.01); 2026-03-11 (items 5.07); 2026-02-05 (items 2.02, 9.01); 2025-12-18 (items 5.02).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.